Stephan Hamperl

Dr. Stephan Hamperl

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Cell
Verified
Journal Article
Closed access
SHStephan Hamperl
Stephan Hamperl
MBMichael J. Bocek
Michael J. Bocek
JSJoshua C. C Saldivar
Joshua C. C Saldivar
TSTomek Swigut
Tomek Swigut
KCKarlene A. Cimprich
Karlene A. Cimprich

1 December 2016 in Cell
Verified
Journal Article
Closed access
SHStephan Hamperl
Stephan Hamperl
KCKarlene A. Cimprich
Karlene A. Cimprich


29 October 2019 in mBio
Verified
Journal Article
Open access
PDF file
DPDagmar Pich
Dagmar Pich
PMPaulina Mrozek-Gorska
Paulina Mrozek-Gorska
MBMickaël Bouvet
Mickaël Bouvet
ASAtsuko Sugimoto
Atsuko Sugimoto
EAEzgi Akidil
Ezgi Akidil
WHWolfgang Hammerschmidt
Wolfgang Hammerschmidt
Epstein-Barr virus (EBV) infects and activates resting human B lymphocytes, reprograms them, induces their proliferation, and establishes a latent infection in them. In established EBV-infected cell lines, many viral latent genes are expressed. Their roles in supporting the continuous proliferation of EBV-infected B cells in vitro are known, but their functions in the early, prelatent phase of infection have not been investigated systematically. In studies during the first 8 days of infection using derivatives of EBV with mutations in single genes of EBVs, we found only Epstein-Barr nuclear antigen 2 (EBNA2) to be essential for activating naive human B lymphocytes, inducing their growth in cell volume, driving them into rapid cell divisions, and preventing cell death in a subset of infected cells. EBNA-LP, latent membrane protein 2A (LMP2A), and the viral microRNAs have supportive, auxiliary functions, but mutants of LMP1, EBNA3A, EBNA3C, and the noncoding Epstein-Barr virus with small RNA (EBERs) had no discernible phenotype compared with wild-type EBV. B cells infected with a double mutant of EBNA3A and 3C had an unexpected proliferative advantage and did not regulate the DNA damage response (DDR) of the infected host cell in the prelatent phase. Even EBNA1, which has very critical long-term functions in maintaining and replicating the viral genomic DNA in established cell lines, was dispensable for the early activation of infected cells. Our findings document that the virus dose is a decisive parameter and indicate that EBNA2 governs the infected cells initially and implements a strictly controlled temporal program independent of other viral latent genes. It thus appears that EBNA2 is sufficient to control all requirements for clonal cellular expansion and to reprogram human B lymphocytes from energetically quiescent to activated cells. IMPORTANCE The preferred target of Epstein-Barr virus (EBV) is human resting B lymphocytes. We found that their infection induces a well-coordinated, time-driven program that starts with a substantial increase in cell volume, followed by cellular DNA synthesis after 3 days and subsequent rapid rounds of cell divisions on the next day accompanied by some DNA replication stress (DRS). Two to 3 days later, the cells decelerate and turn into stably proliferating lymphoblast cell lines. With the aid of 16 different recombinant EBV strains, we investigated the individual contributions of EBV’s multiple latent genes during early B-cell infection and found that many do not exert a detectable phenotype or contribute little to EBV’s prelatent phase. The exception is EBNA2 that is essential in governing all aspects of B-cell reprogramming. EBV relies on EBNA2 to turn the infected B lymphocytes into proliferating lymphoblasts preparing the infected host cell for the ensuing stable, latent phase of viral infection. In the early steps of B-cell reprogramming, viral latent genes other than EBNA2 are dispensable, but some, EBNA-LP, for example, support the viral program and presumably stabilize the infected cells once viral latency is established.

2 December 2012 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
THThomas Hierlmeier
Thomas Hierlmeier
JMJuliane Merl-Pham
Juliane Merl-Pham
MSMartina Sauert
Martina Sauert
JFJorge Pérez Fernández
Jorge Pérez Fernández
PSPatrick Schultz
Patrick Schultz
HTHerbert Tschochner
Herbert Tschochner
Eukaryotic ribosome biogenesis requires more than 150 auxiliary proteins, which transiently interact with pre-ribosomal particles. Previous studies suggest that several of these biogenesis factors function together as modules. Using a heterologous expression system, we show that the large ribosomal subunit (LSU) biogenesis factor Noc1p of Saccharomyces cerevisiae can simultaneously interact with the LSU biogenesis factor Noc2p and Rrp5p, a factor required for biogenesis of the large and the small ribosomal subunit. Proteome analysis of RNA polymerase-I-associated chromatin and chromatin immunopurification experiments indicated that all members of this protein module and a specific set of LSU biogenesis factors are co-transcriptionally recruited to nascent ribosomal RNA (rRNA) precursors in yeast cells. Further ex vivo analyses showed that all module members predominantly interact with early pre-LSU particles after the initial pre-rRNA processing events have occurred. In yeast strains depleted of Noc1p, Noc2p or Rrp5p, levels of the major LSU pre-rRNAs decreased and the respective other module members were associated with accumulating aberrant rRNA fragments. Therefore, we conclude that the module exhibits several binding interfaces with pre-ribosomes. Taken together, our results suggest a co- and post-transcriptional role of the yeast Rrp5p–Noc1p–Noc2p module in the structural organization of early LSU precursors protecting them from non-productive RNase activity.

1 May 2011 in Cell
Verified
Journal Article
Closed access
MWManuel Wittner
Manuel Wittner
SHStephan Hamperl
Stephan Hamperl
USUlrike Stöckl
Ulrike Stöckl
WSWolfgang Seufert
Wolfgang Seufert
HTHerbert Tschochner
Herbert Tschochner
JGJoachim Griesenbeck
Joachim Griesenbeck